Gilead Sciences Financial Ratios
NASDAQ: GILDHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Gilead Sciences ratio analysis
Gilead Sciences earned a net margin of 28.9% in FY 2025, up from 1.7% a year earlier. Gross margin was 78.8% compared with a median of 79.2% over the prior 9 years. Return on equity reached 37.5%, meaning Gilead Sciences generated 0.37 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 1.10 versus 1.38 the year before, and the current ratio was 1.55. At the end of FY 2025, GILD traded at 17.9 times earnings; across the 10 fiscal years shown, its year-end P/E ranged from 7.2 to 582.6, with a median of 18.0. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Gilead Sciences financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 17.94 | 240.55 | 18.00 | 23.59 | 14.73 | 582.60 | 15.42 | 16.37 | 20.41 | 7.20 |
| Price / sales | 5.14 | 3.96 | 3.73 | 3.95 | 3.34 | 2.97 | 3.68 | 4.00 | 3.59 | 3.16 |
| Price / book | 6.66 | 5.90 | 4.43 | 5.07 | 4.33 | 4.02 | 3.67 | 4.14 | 4.58 | 5.08 |
| Gross margin | 78.8% | 78.3% | 76.0% | 79.3% | 75.8% | 81.5% | 79.2% | 78.1% | 83.3% | 86.0% |
| Operating margin | 34.0% | 5.8% | 28.0% | 26.9% | 36.3% | 16.5% | 19.1% | 37.1% | 54.1% | 58.0% |
| Net margin | 28.9% | 1.7% | 20.9% | 16.8% | 22.8% | 0.5% | 24.0% | 24.7% | 17.7% | 44.4% |
| Free cash flow margin | 32.1% | 35.8% | 27.4% | 30.6% | 39.6% | 30.5% | 37.1% | 33.8% | 43.3% | 53.6% |
| Return on equity (ROE) | 37.5% | 2.5% | 24.8% | 21.6% | 29.5% | 0.7% | 23.9% | 25.5% | 22.6% | 71.5% |
| Return on assets (ROA) | 14.4% | 0.8% | 9.1% | 7.3% | 9.2% | 0.2% | 8.7% | 8.6% | 6.6% | 23.7% |
| Debt / equity | 1.10 | 1.38 | 1.09 | 1.19 | 1.27 | 1.73 | 1.09 | 1.28 | 1.64 | 1.39 |
| Current ratio | 1.55 | 1.60 | 1.43 | 1.29 | 1.27 | 1.40 | 3.10 | 3.38 | 2.74 | 2.12 |
| Revenue growth | 2.4% | 6.0% | -0.6% | -0.1% | 10.6% | 10.0% | 1.5% | -15.2% | -14.1% | -6.9% |
| EPS growth | 1,684.2% | -91.6% | 23.6% | -26.2% | 4,830.0% | -97.6% | 1.2% | 18.8% | -64.7% | -16.5% |